Nextech Invest

Nextech Invest is a global venture capital firm headquartered in Zurich, Switzerland, with affiliate offices in Boston and San Francisco. The firm is dedicated to finding and fueling advances in precision medicine, with a primary focus on identifying and supporting emerging biotechnology companies developing transformative cancer medicines and therapies for oncology-adjacent disease areas. They are active investors, closely engaging with their portfolio companies to drive value creation through critical moments of scientific validation and development.

Founded in 1998, Nextech Invest launched its first worldwide oncology fund in late 2006, demonstrating a long-standing commitment to the biotechnology and life sciences sectors. The firm's investment strategy spans various stages, from Series A to publicly listed investments, and encompasses companies from discovery to clinical development.

The firm's portfolio includes notable investments in companies such as Revolution Medicines, Tyra Biosciences, ORIC Pharmaceuticals, CARGO Therapeutics, and Arvinas. They have also supported companies like Atavistik Bio, Parabilis Medicines, and Tango Therapeutics, focusing on drug discovery and innovative therapeutic platforms, including RNA editing and antibody-drug conjugates.

Nextech Invest prides itself on fusing unrivaled worldwide scientific expertise with unmatched investment rigor. The team comprises experienced professionals and science partners like Karl-Heinz Altmann, Ph.D., Benjamin Cravatt, Ph.D., Chairman Alexis Borisy, and Managing Partners Thilo Schroeder, Ph.D., and Kanishka Pothula. This blend of scientific knowledge and investment acumen allows them to provide hands-on support and strategic guidance to their portfolio companies.